Posted On: 08/24/2016 8:26:26 PM
Post# of 405
Interesting segment today on CNBC about The Epipen costs going up drastically and how the FDA ties in.
Bottom line takeaway from the back and forth was - FDA should get moving on more generic drug approvals as they will bring costs DOWN and create more competition. Clearly, they cater to big Pharma but the segment made them look BAD IMO.
http://video.cnbc.com/gallery/?video=3000545665
** Pitts was once one of their own
Bottom line takeaway from the back and forth was - FDA should get moving on more generic drug approvals as they will bring costs DOWN and create more competition. Clearly, they cater to big Pharma but the segment made them look BAD IMO.
http://video.cnbc.com/gallery/?video=3000545665
** Pitts was once one of their own
(1)
(0)
